Clinical trials: Plasmodium Falciparum Malaria
Malaria, Plasmodium Falciparum
Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe
This is an open label, human pilot study to optimise controlled human malaria infection (CHMI) administered by Plasmodium falciparum sporozoites (PfSPZ. Volunteers will be inoculated with PfSPZ Challenge.
- Trial name
- NCT01465048
- Testing
- Plasmodium falciparum sporozoites 2sites, Plasmodium falciparum sporozoites 1 site, Plasmodium falciparum sporozoites 1site
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Evaluate the Safety and Efficacy of Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered With Adjuvant AS01B
The purpose of this study is to determine whether an investigational malaria vaccine is safe and induces an immune response against malaria when tested in adults living in the United States.
- Trial name
- NCT02458092
- Testing
- Plasmodium falciparum Malaria Protein 010 (FMP010), Rabipur
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Falciparum Malaria
Efficacy of ArTiMist™ in Children
The purpose of this study is to compare the efficacy of Artemether Sublingual Spray (ArTiMist™) with intravenous quinine in children with severe or complicated falciparum malaria, or children with uncomplicated malaria with…
- Trial name
- NCT01047436
- Testing
- Quinine, Artemether
- Volunteers
- 31 people
- Sponsor
- Proto Pharma Ltd
Malaria,Falciparum
The Impact RTS,S/AS01 Vaccine in School Aged Children RTS,S/AS01 Malaria Vaccine in School Aged Children
Across sub-Saharan Africa, school-age children bear an under-appreciated burden of malaria. An estimated 200 million school-age children are at risk of malaria and in many areas prevalence of infection exceeds 50%.
- Trial name
- NCT06424002
- Testing
- Mosquirixs, artemether-lumefantrine
- Volunteers
- 5,400 people, healthy volunteers welcome
- Sponsor
- Kamuzu University of Health Sciences
Falciparum Malaria
Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Malaria in Cameroon
Malaria remains a major public health concern in Cameroon especially among vulnerable groups such as children less than five years and pregnant women.
- Trial name
- NCT04829695
- Testing
- Artesunate-amodiaquine drug combination, Artemether-lumefantrine drug combination
- Volunteers
- 184 people
- Sponsor
- University of Yaounde 1
Malaria (Plasmodium Falciparum)
Malaria CVD 36000; Gates INV090205
In order to control infections, the investigators must first detect them. Biosensor devices may allow early detection and intervention for infectious diseases, helping the investigators to recognize infections early, and allow…
- Trial name
- NCT07558122
- Testing
- PfSPZ Challenge (NF54), Wearable Biosensor Devices
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Malaria, Vivax Malaria
Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas
This study is designed as a multi-centre randomized, open label trial to compare the safety and efficacy of a high dose primaquine (PQ) treatment in G6PD normal patients with P. falciparum to reduce the risk of subsequent P.
- Conditions
- Malaria, Vivax Malaria, Falciparum Malaria
- Trial name
- PRIMA (NCT03916003)
- Testing
- primaquine
- Where
- 3 sites in Bangladesh, Ethiopia and 1 more
- Volunteers
- 500 people
- Sponsor
- Menzies School of Health Research
Malaria, Falciparum, HIV Infections
Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi
In Malawi, the standard of care to prevent malaria during pregnancy at the time of the study was a two dose sulfadoxine-pyrimethamine intermittent protective treatment (SP IPT) regimen administered in the second and third…
- Trial name
- NCT00126906
- Testing
- Monthly sulfadoxine/pyrimethamine, 2-dose sulfadoxine/pyrimethamine
- Where
- Malawi
- Volunteers
- 700 people
- Sponsor
- Centers for Disease Control and Prevention
Falciparum Malaria
Azithromycin Combination Therapy for the Treatment of Severe Malaria
A randomized controlled trial to assess the safety and efficacy of azithromycin combination therapy for use in severe malaria. This pilot trial will be conducted in uncomplicated malaria patients in southeastern Bangladesh.
- Trial name
- NCT01374126
- Testing
- Artesunate, Azithromycin + Artesunate
- Where
- Bangladesh
- Volunteers
- 75 people
- Sponsor
- Medical University of Vienna
Malaria,Falciparum
A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™
This is a phase I clinical study that aims to assess the safety and immunogenicity of a novel, escalating dose regimen of R21/Matrix-M™ in healthy, malaria-naïve adults.
- Trial name
- NCT06320535
- Testing
- R21/Matrix M™ (Group 1), R21/Matrix M™ (Group 2), R21/Matrix M™ (Group 3)
- Where
- 2 sites in United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
A Randomised Efficacy Study of Combination Antimalarials to Treat Uncomplicated Malaria
The purpose of this study is to determine the efficacy of sulfadoxine-pyrimethamine plus artesunate versus sulfadoxine-pyrimethamine alone in the treatment of uncomplicated malaria.
- Trial name
- NCT00203814
- Testing
- Sulfadoxine-pyrimethamine, Artesunate plus sulfadoxine-pyrimethamine
- Where
- 2 sites in Mozambique
- Volunteers
- 280 people
- Sponsor
- University of Cape Town
Asymptomatic P.Falciparum Malaria
Artemisia Annua Infusion for the Treatment of Asymptomatic Plasmodium Falciparum Infection
The goal of this clinical trial is to determine whether Artemisia annua dried leaves, used as an infusion, can treat individuals with malaria parasites but no symptoms.
- Trial name
- ART-CT001 (NCT07819825)
- Testing
- Artemisia Annua Leaf, Centaurii herba
- Where
- Gabon
- Volunteers
- 20 people
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Malaria
Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults
Malaria has remained a major concern for the US military. During World War II, malaria was the leading cause of disease and non-battle injury with 500-700 men infected per day, resulting in 24,000 malaria-related casualties.(10)…
- Trial name
- NCT01540474
- Testing
- Group 1: 10 ug FMP012 with 2 ug GLA-SE, Group 2: 10 ug FMP012 with 5 ug GLA-SE, 50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Plasmodium Falciparum Malaria
Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali
Malaria is a disease that affects many people in Africa. Malaria is caused by germs spread by mosquito bites. The purpose of this study is to compare the number of children who get malaria after receiving an experimental malaria…
- Trial name
- NCT00460525
- Testing
- FMP2.1/AS02A, Rabies Vaccine
- Where
- Mali
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Plasmodium Falciparum Malaria
Malarial Immunity in Pregnant Cameroonian Women
Malaria is caused by a parasite and is a health problem for mothers and fetuses (unborn infants). The Cameroonian Ministry of Health recommends that all pregnant women should take the drug sulfadoxine-pyrimethamine (also known as…
- Trial name
- NCT00593398
- Where
- Cameroon
- Volunteers
- 990 people, healthy volunteers welcome
- Sponsor
- University of Hawaii
Malaria
Artesunate Plus Sulfadoxine-pyrimethamine Pharmacokinetics, Efficacy, Gametocytes Carriage and Birth Outcomes in Pregnant Women With Malaria
The main purpose of this study is to compare the drug levels of artesunate and sulfadoxine-pyrimethamine found in pregnant women with malaria to those drug levels found in non-pregnant women from other studies.
- Trial name
- NCT00331708
- Testing
- Artesunate plus sulfadoxine-pyrimethamine
- Where
- Mozambique
- Volunteers
- 3 people
- Sponsor
- Professor Karen I Barnes
Malaria, Fever
Examination of ACT Implementation in a Vivax / Falciparum Co-endemic Area
In areas of which are co-endemic for vivax and falciparum malaria, treatments for the two diseases often differ and this may lead to mistreatment. This places an emphasis on diagnosis at the health service provision level.
- Trial name
- NCT00935688
- Testing
- Rapid diagnostic test
- Where
- 2 sites in Afghanistan
- Volunteers
- 4,200 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Plasmodium Falciparum Malaria
Experimental Vaccine for Malaria in Adults in Mali
This study will determine the highest dose of an experimental vaccine called AMA1-C1 that can safely be given to adults exposed to malaria.
- Trial name
- NCT00343005
- Testing
- AMA1-C1, AMA1-C1/alhydrogel Malaria Vaccine
- Where
- Mali
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasmodium Falciparum Malaria
Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria
The primary trial objective is to determine the clinically effective dose of orally administered pyronaridine/artesunate (Pyramax®, PA) with a 3:1 ratio to treat adults with acute, symptomatic, uncomplicated P.
- Trial name
- NCT01594931
- Testing
- pyronaridine/artesunate
- Where
- 6 sites in Cambodia, Indonesia and 4 more
- Volunteers
- 477 people
- Sponsor
- Medicines for Malaria Venture
Malaria, Plasmodium Falciparum
A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5
The purpose of this study is to assess two new malaria vaccines, ChAd63 RH5 and MVA RH5, at different doses and alone or in combination.
- Trial name
- NCT02181088
- Testing
- ChAd63 RH5 low dose, ChAd63 RH5 full dose, MVA RH5 low dose
- Where
- 2 sites in United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Oxford